Johanna K. Kaufmann, PhD, Executive Vice President of Oncology at Codagenix, leads the company’s efforts in developing virotherapeutic candidates for breast cancer and other solid tumors. Codagenix is a clinical-stage biotechnology company committed to building the world's most agile, adaptable, and powerful vaccine platform to discover and develop prophylactic viral vaccines and immunotherapies for cancer.
Oncolytic viruses have the power to make the tumor more visible to the immune system and mark the area of attack. It is this anti-tumor immune activation that has the potential to induce long-term responses in patients.